Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488041 | 0.87 | SIGMAR1 (0.47) | MMP1MMP13ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL13434254 | 0.85 | CYP3A4 (0.47) | MMP1MMP13CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL3488893 | 0.83 | KMT2A (0.56) | CYP3A4CYP2C19ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL3488361 | 0.81 | SMN1; SMN2 (0.55) | CYP3A4CYP2C19ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL17062184 | 0.80 | GAA (0.50) | MMP1MMP13CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL16759341 | 0.80 | GAA (0.50) | MMP1MMP13CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL2242813 | 0.80 | SIGMAR1 (0.48) | ALDH1A1LMNASIGMAR1 | |
| SCHEMBL16485924 | 0.78 | KMT2A (0.53) | CYP3A4CYP2C19ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL16485861 | 0.77 | GAA (0.50) | MMP1MMP13CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL28050302 | 0.77 | ALDH1A1 (0.49) | MMP1MMP13CYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | MMP1 610/4885MMP13 1349/4885CYP3A4 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.